Member Info for technick

Just not enough exposure to get this trading... our time will come!

wonder if one of Herules' Pharma companies might be a candidate to reverse into motif, seems as though there's already a plan being worked

it is interesting. One of the larger players such as GE could see IQAI as an interesting acquisition target and a quick way of adding value to their product range. Now is the cheapest time to acquire. There was a subtle shift in commercialisation discussion in the pre-FDA announcement where Cortech's was the route to market, to the post-FDA announcement where the Company was exploring opportunities including with the equipment manufacturers. That had not been raised before unless someone else can correct me? I would not be surprised if something is not brewing in the background as per the last RNS...

I tend to agree hasiba, it remains to be seen how much of it becomes diluted in the struggle to keep the business afloat but we can only wait and see. The brave will average down in the hope that it's not a foolish move. I still believe in the product and its potential to save lives. At the very least it needs to get to market so I can justify my losses here... Come on BOD find a buyer who can make that happen

'kind help and support', anybody else think that is a slightly patronising response? The Company really needs to pull their finger out here, they have a very innovative class leading product in the market, please don't drop this ball Mr Walls...

Yes thank you for sharing. Exciting times, there will be commercial deals given the product and regulatory position which makes this an exciting business. There are few medical AI companies that are listed again making this an interesting company. Coming up to a year I invested here and I have no complaints at all...

A lot to digest in the circular this morning. I'm not fully understanding the Hercules loan transaction, are they swapping the entirety of the loan into options or is it only the interest element. If its the former then that would show some indication of value they perceive going forward. Similarly the transfer of deferred payments to the NED into options seems positive though it could be argued they have no choice. Wiping of executive options is a joke, presumably the strike price is so high as to make them impossible to achieve now so what was the point in positioning this as a 'positive'? I am convinced that there is value, the world needs new antibiotics. It will be sold either before or after the shell and no doubt Hercules has a candidate to reverse into it and hence their pragmatism... Agree with the sentiment around loss recovery, there is no chance unless anyone was able to average down. I couldn't bring myself to average down aggressively enough based on the poor performance of the board. They missed the obvious need to include liver toxicity in their FDA study based on previous concerns, consequently it left open questions and the FDA reacted accordingly. All imo

With the FDA clearance it must make it attractive to manufacturers to bundle and provide a competitive advantage. Let's see what the coming weeks bring but things definitely look really good here.

Re-reading the last RNS after FDA it does look as though the next announcement may be around a strategic partnership with a large equipment provider such as GE... That would be a great boost as minimum sales numbers could be readily defined. Relationships with key strategic partners for StoneChecker have been cultivated for some time, including discussions with companies that are CT technology providers, suppliers of lithotripsy equipment and companies specializing in the kidney sector which sell directly to kidney specialists. These discussions are continuing, as we evaluate how best to optimize the commercial opportunities provided by last week's FDA clearance.

I believe there would also need to be notification because of her shareholding unless it is below the threshold? Yesterdays flurry of share trading was a little odd... Agree, a lot of potential here and a decent discussion board compared to others

The company's value was heavily linked to that FDA approval but clearly there are other opportunities and unless someone says otherwise, other markets outside the US and their regulatory process that could be sold into prior to approvals in the US? I'm not convinced this is completely dead but I am an optimist! Interesting...

Agree Troy, and the AIHL opportunity is not solely UK opportunity. If we say the UK is 1% of the world population it could be a massive opportunity if rolled out into other territories. There are also other pharmacogenomic tests to be had I'm sure - tailored therapy is the future. The platform is now seemingly developed and completed successful studies and deployment with the DOD so it now represents a basis on which to deploy further tests. As I mentioned the other day the risk is the low share price - it could represent a takeover target though this is somewhat reduced by the fact that 50%+ of shares is institutional which should mean a fair valuation. Current brokers note suggests a 60p target price which is 3x the current SP, I'm sure this will be updated shortly to be higher based on recent news flow. In for the long term here having held for a few years, it looks like the company is getting where they need to get to.

Some large trades compared to normal volume... £10.5k is a large trade for GDR

Something must be up here? Obviously a lot of potential but its been off the radar for a while, nice to see some trading volume

spread currently nearly 30%

It will be interesting to see if the trend continues upwards today. Regardless, the market cap has been influenced on very small trading volume and wide spread. The business on paper is undervalued in my opinion and can only be from the pressure of a seller who may have now gone away...

Let's hope for some positive and steady share price movement now based on further sales and development... at £5m and positive news flow it must be on the radar of one of the large diagnostics Companies too! A long way to go but there are comparisons in the same market https://www.genomeweb.com/pcr/roche-acquires-poc-mdx-firm-iquum

I agree Troy. I think the chairman did by a few earlier in the year but I would have hoped with the large salaries the executives are earning and their options that they’d buy in the market more than they have. This will come good, it is becoming a better story everyday

Who sells £56 & £63 worth of shares and how can this cause a £170k drop in market cap? I simply don't understand on both counts and these low liquidity shares always throws up 'odd' trading behaviour. Perhaps there's something being 'managed' in the background? Does anyone have any thoughts? My personal opinion is that at some point this becomes and attractive trade sale and we may see some options awarded soon... cynical?

I've been invested here a while. I suspect that since the FDA approval that other commercial opportunities have happened and the they have suddenly appeared on the radar of several of the larger equipment suppliers. If you listen to the last Proactive Investor presentation the Company makes a point of saying that they are exploring commercial opportunities which they'd announce. In my opinion no news is good news as it may represent a more strategic partnership or exclusive deal. All just opinion but I continue to hold and think that the BOD have done a good job to raise value with minimal dilution to shareholders.